Localization and Accumulation Studies of Dacomitinib in Rat Intestines and Skin by Immunohistochemistry
-
Published:2019-12-27
Issue:6
Volume:52
Page:101-106
-
ISSN:0044-5991
-
Container-title:ACTA HISTOCHEMICA ET CYTOCHEMICA
-
language:en
-
Short-container-title:Acta Histochem. Cytochem
Author:
Yamamoto Yutaro1, Saita Tetsuya1, Oka Asuki1, Kataoka Hiroto1, Shin Masashi1
Affiliation:
1. Applied Life Science Department, Faculty of Biotechnology and Life Science, Sojo University
Publisher
Japan Society of Histochemistry & Cytochemistry
Subject
Cell Biology,Histology,Physiology,Biochemistry,Pathology and Forensic Medicine
Reference11 articles.
1. 1 Ding, P. N., Lord, S. J., Gebski, V., Links, M., Bray, V., Gralla, R. J., Yang, J. C. and Lee, C. K. (2017) Risk of treatment-related toxicities from EGFR tyrosine kinase inhibitors: a meta-analysis of clinical trials of gefitinib, erlotinib, and afatinib in advanced EGFR-mutated non-small cell lung cancer. J. Thorac. Oncol. 12; 633–643. 2. 2 Gajiwala, K. S., Feng, J., Ferre, R., Ryan, K., Brodsky, O., Weinrich, S., Kath, J. C. and Stewart, A. (2013) Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition. Structure 21; 209–219. 3. 3 Green, M. R., Basketter, D. A., Couchaman, J. R. and Rees, D. A. (1983) Distribution and number of epidermal factor receptors in skin is related to epithelial cell growth. Dev. Biol. 100; 506–512. 4. 4 Ou, S. H. (2012) Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence. Crit. Rev. Oncol. Hematol. 83; 407–421. 5. 5 Park, K., Tan, E. H., O’Byrne, K., Zhang, L., Boyer, M., Mok, T., Hirsh, V., Yang, J. C., Lee, K. H., Lu, S., Shi, Y., Kim, S. W., Laskin, J., Kim, D. W., Arvis, C. D., Kölbeck, K., Laurie, S. A., Tsai, C. M., Shahidi, M., Kim, M., Massey, D., Zazulina, V. and Paz-Ares, L. (2016) Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 17; 577–589.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|